3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
4
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
79
Carcinoma, Renal Cell
36
Neoplasms
35
Liver Neoplasms
22
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
7
Neoplasm Metastasis
6
Melanoma
5
Thyroid Neoplasms
4
Kidney Neoplasms
4
Breast Neoplasms
3
Financial Stress
2
Vaccinia
1
Stomach Neoplasms
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoma
1
Lung Neoplasms
1
Liver Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulin-Like Growth Factor I, Resistance To
1
Hypophosphatemia
1
Hepatitis C
1
Hepatitis B
1
Glioblastoma
1
Digestive System Neoplasms
1
Interventions
Capecitabine
77
pembrolizumab
70
Oxaliplatin
68
Cisplatin
56
Fluorouracil
52
Paclitaxel
41
Trastuzumab
37
Nivolumab
35
Leucovorin
27
Docetaxel
27
Irinotecan
22
Ramucirumab
20
Gemcitabine
15
Bevacizumab
15
S 1 (combination)
14
Carboplatin
13
atezolizumab
12
apatinib
12
fludarabine
11
Cyclophosphamide
11
tislelizumab
10
Drug Therapy
10
Injections
8
130-nm albumin-bound paclitaxel
8
trastuzumab deruxtecan
7
durvalumab
7
Ipilimumab
7
Folfox protocol
7
Albumin-Bound Paclitaxel
7
titanium silicide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Neoplasms
×
Sorafenib
×
Clear all
NCT00663741
2013-06-11
Sorafenib Gastric Cancer Asian Phase I Study
Bayer
Phase 1
Completed
13 enrolled